PMC:7597510 / 1555-1772 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T27","span":{"begin":63,"end":71},"obj":"Disease"},{"id":"T28","span":{"begin":74,"end":83},"obj":"Disease"},{"id":"T29","span":{"begin":92,"end":95},"obj":"Disease"}],"attributes":[{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"}],"text":"till no reports in Japan.3 However, in a review of 37 cases of SARS-CoV-2-infection-related GBS, less than half of the studies investigated antiganglioside antibodies.4 Furthermore, few reports have provided details r"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T5","span":{"begin":39,"end":40},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"till no reports in Japan.3 However, in a review of 37 cases of SARS-CoV-2-infection-related GBS, less than half of the studies investigated antiganglioside antibodies.4 Furthermore, few reports have provided details r"}

{"project":"LitCovid-PubTator","denotations":[{"id":"53","span":{"begin":63,"end":83},"obj":"Disease"}],"attributes":[{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"till no reports in Japan.3 However, in a review of 37 cases of SARS-CoV-2-infection-related GBS, less than half of the studies investigated antiganglioside antibodies.4 Furthermore, few reports have provided details r"}